SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Laverman, G. D
Right arrow Articles by Navis, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laverman, G. D
Right arrow Articles by Navis, G.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Kidney Diseases
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy?

Gozewijn D Laverman

Department of Medicine, Division of Nephrology, University of Groningen, GD_Laverman@ hotmail.com, Mario Negri Institute for Pharmacological Research, Bergamo, Italy

Dick de Zeeuw

Department of Medicine, Division of Nephrology, University of Groningen, Department of Clinical Pharmacology, University of Groningen, The Netherlands

Gerjan Navis

Department of Medicine, Division of Nephrology, University of Groningen, Department of Clinical Pharmacology, University of Groningen, The Netherlands

Renin-angiotensin-aldosterone system (RAAS) blockade with angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin II (Ang II), AT1receptor blockers (ARB) is the cornerstone of renoprotective therapy. Still, the number of patients with end-stage renal disease is increasing worldwide, prompting the search for improved renoprotective strategies.

In spite of proven efficacy at group level, the long-term renoprotective effect of RAAS blockade displays a marked between-patient heterogeneity, which is closely linked to between-patient differences in the intermediate parameters of blood pressure, proteinuria and renal haemodynamics. Of note, the between-patient differences by far exceed the between-regimen differences, and thus may provide a novel target for exploration and intervention.

The responsiveness to RAAS blockade appears to be an individual characteristic — as demonstrated by studies applying a rotation-schedule design. The type and severity of renal disease, obesity, insulin-resistance, glycaemic control, and genetic factors may all be involved in individual differences in responsiveness, as well as dietary factors, such as dietary sodium and protein intake.

Several strategies, such as dietary sodium restriction and diuretic therapy, dose-titration for proteinuria, and dual RAAS blockade with ACE-I and ARB, can improve the response to therapy at a group level. However, when analysed for their effect in individuals, it appears that these measures do not allow poor responders to catch up with the good responders, i.e. in spite of their efficacy at group level, the available measures are usually not sufficient to overcome individual resistance to RAAS blockade.

We conclude that between-patient differences in responsiveness to renoprotective intervention should get specific attention as a target for intervention. Unravelling of the underlying mechanisms may allow development of specific intervention. Based on the currently available data, we propose that response-based treatment schedules, with a multidrug approach titrated and adapted at individual responses rather than fixed treatment schedules, may provide a fruitful strategy for more effective renoprotection.

Key Words: therapy-response • patient factors • RAAS-blockade • renoprotection • sodium status

References

  • Lewis EJ, Hunsicker LG, Bain RP, Rohde RD The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.[Abstract/Free Full Text]
  • Jafar TH, Schmid CH, Landa M. et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87.[Abstract/Free Full Text]
  • Maschio G., Alberti D., Janin G. et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334:939-45.[Abstract/Free Full Text]
  • Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.[Abstract/Free Full Text]
  • Brenner BM, Cooper ME, De Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.[Abstract/Free Full Text]
  • Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353:2008-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Apperloo AJ, De Zeeuw D., De Jong PE A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997;51:793-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Apperloo AJ, De Zeeuw D., De Jong PE Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 1994;45(suppl):S174-S178.[Web of Science]
  • Rossing P., Hommel E., Smidt UM, Parving HH Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994;37:511-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Eddy AA, Giachelli CM Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 1995;47:1546-57.[Web of Science][Medline] [Order article via Infotrieve]
  • Zoja C., Benigni A., Remuzzi G. Protein overload activates proximal tubular cells to release vasoactive and inflammatory mediators. Exp Nephrol 1999;7:420-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Abbate M., Zoja C., Rottoli D. et al.Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates pro. J Am Soc Nephrol 1999;10:804-13.[Abstract/Free Full Text]
  • JafarTH, Stark PC, Schmid CH et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001;60:1131-40.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ruggenenti P., Schieppati A., Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001;357: 1601-08.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Praga M. Slowing the progression of renal failure. Kidney Int 2002;61(suppl 80):18-22.[CrossRef]
  • De Jong PE, Navis G., De Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 1999;354:352-3.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bos H.,Andersen S., Rossing P. et al. Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney Int 2000;57:S32-S37.[CrossRef][Web of Science]
  • Ruggenenti P., Perna A., Gherardi G., Benini R., Remuzzi G. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000;35:1155-65.[Web of Science][Medline] [Order article via Infotrieve]
  • Ruggenenti P., Remuzzi G. Nephropathy in NIDDM patients, predictors of outcome, chapter 20. In: Mogensen CE (eds.). The kidney and hypertension in diabetes mellitus, 1edition. Boston- Dordrecht -London: Kluwer Academic Publishers, 2000;237-46.
  • Lufft V., Kliem V., Hamkens A. et al. Antiproteinuric efficacy of fosinopril after renal transplantation is determined by the extent of vascular and tubulointerstitial damage. Clin Transplant 1998;12:409-15.[Web of Science][Medline] [Order article via Infotrieve]
  • Kramer AB, Laverman GD, van Goor H., Navis GJ Interindividual differences in antiproteinuric response to ACEi in established adriamycin nephrosis are predicted by pre-treatment renal damage. J Pathol 2003, provisionally accepted for publication.
  • Perico N.,Amuchastegui SC, Colosio V., Sonzogni G., Bertani T., Remuzzi G. Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started.JAm Soc Nephrol 1994;5:1139-46.[Abstract]
  • Ruggenenti P., Perna A., Remuzzi G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 2001;12: 2832-7.[Abstract/Free Full Text]
  • Bos H., Henning RH, De Jong PE, De Zeeuw D., Navis G. Do severe systemic sequelae of proteinuria modulate the antiproteinuric response to chronic ACE inhibition? Nephrol Dial Transplant 2002;17:793-7.[Abstract/Free Full Text]
  • Navis G., de Jong P., Donker AJ, van der Hem GK, De Zeeuw D. Diuretic effects of angiotensin-converting enzyme inhibition: comparison of low and liberal sodium diet in hypertensive patients. J Cardiovasc Pharmacol 1987;9:743-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Navis G., De Jong PE, Donker AJ, van der Hem GK, De Zeeuw D. Moderate sodium restriction in hypertensive subjects: renal effects of ACE-inhibition. Kidney Int 1987;31:815-19.[Web of Science][Medline] [Order article via Infotrieve]
  • Heeg JE, De Jong PE, van der Hem GK, De Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989;36:272-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Buter H., Hemmelder MH, Navis G., De Jong PE, De Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998;13:1682-5.[Abstract/Free Full Text]
  • Gansevoort RT, De Zeeuw D., De Jong PEAdditive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease. Nephrol Dial Transplant 1995;10:497-504.[Abstract/Free Full Text]
  • Praga M. Obesity - a neglected culprit in renal disease. Nephrol Dial Transplant 2002;17:1157-9.[Free Full Text]
  • Praga M., Hernandez E., Morales E. et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2001;16:1790-8.[Abstract/Free Full Text]
  • Price DA, Lansang MC, Osei SY, Fisher ND, Laffel LM, Hollenberg NK Type 2 diabetes, obesity, and the renal response to blocking the renin system with irbesartan. Diabet Med 2002;19:858-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rocchini AP Obesity hypertension. Am J Hypertens 2002; 15:50S-52S.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans.NEnglJMed 1996;334:292-5.[Abstract/Free Full Text]
  • Wolf G., Hamann A., Han DC et al. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int 1999;56:860-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wolf G., Chen S., Han DC, Ziyadeh FN Leptin and renal disease. Am J Kidney Dis 2002;39:1-11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gorzelniak K., Engeli S., Janke J., Luft FC, Sharma AM Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens 2002;20:965-73.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Osei SY, Price DA, Fisher ND, Porter L., Laffel LM, Hollenberg NK Hyperglycemia and angiotensin-mediated control of the renal circulation in healthy humans. Hypertension 1999;33:559-64.[Abstract/Free Full Text]
  • Osei SY, Price DA, Laffel LM, Lansang MC, Hollenberg NK Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans. Hypertension 2000;36:122-6.[Abstract/Free Full Text]
  • Lansang MC, Price DA, Laffel LM et al. Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus. Kidney Int 2001;59:1432-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Laffel LM, Price DA, Hollenberg NK Glycemic control and plasma renin activity predict renal hemodynamic response to captopril in normotensive normoalbuminuric patients with IDDM. (abstract) J Am Soc Nephrol 1998;9:117A.[CrossRef]
  • McLeod HL, Evans WE Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001;41:101-21.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Weir MR, Gray JM, Paster R., Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. Hypertension 1995;26:124-30.[Abstract/Free Full Text]
  • Hollenberg NK, Anzalone DA, Falkner B. et al. Familial factors in the antihypertensive response to lisinopril. Am J Hypertens 2001;14:218-23.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Barlassina C., Schork NJ, Manunta P. et al. Synergistic effect of alpha-adducin and ACE genes causes blood pressure changes with body sodium and volume expansion. Kidney Int 2000;57:1083-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Jordan J.,Tank J., Shannon JR et al. Baroreflex buffering and susceptibility to vasoactive drugs. Circulation 2002;105:1459-64.[Abstract/Free Full Text]
  • Tank J., Jordan J., Diedrich A. et al. Genetic influences on baroreflex function in normal twins. Hypertension 2001;37: 907-10.[Abstract/Free Full Text]
  • Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6.[Web of Science][Medline] [Order article via Infotrieve]
  • Mayer G. ACE genotype and ACE inhibitor response in kidney disease: a perspective. Am J Kidney Dis 2002;40:227-35.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ruggenenti P., Perna A., Zoccali C. et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). J Am Soc Nephrol 2000;11:88-96.[Abstract/Free Full Text]
  • Der Kleij FG, De Jong PE, Henning RH, De Zeeuw D., Navis G.: Enhanced responses of blood pressure, renal function, and aldosterone to angiotensin I in the DD genotype are blunted by low sodium intake. J Am Soc Nephrol 2002;13:1025-33.[Abstract/Free Full Text]
  • van der Kleij FG, Schmidt A., Navis GJ et al. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status. Kidney Int 1997;63(suppl):S23-S26.[CrossRef]
  • Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001;37:739-43.[Abstract/Free Full Text]
  • Praga M., Hernandez E., Andres A., Leon M., Ruilope LM, Rodicio JL Effects of body-weight loss and captopril treatment on proteinuria associated with obesity. Nephron 1995;70:35-41.[Web of Science][Medline] [Order article via Infotrieve]
  • van Paassen P., De Zeeuw D., Navis G., De Jong PE Does the renin-angiotensin system determine the renal and systemic hemodynamic response to sodium in patients with essential hypertension? Hypertension 1996;27:202-08.[Abstract/Free Full Text]
  • van Paassen P., Navis GJ, De Jong PE, De Zeeuw D. Pretreatment renal vascular tone predicts the effect of specific renin inhibition on natriuresis in essential hypertension. Eur J Clin Invest 1999;29:1019-26.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bos H., Henning RH, De Boer E. et al. Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis. Kidney Int 2002;61:473-80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Haas M., Leko-Mohr Z., Erler C., Mayer G. Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy. Am J Kidney Dis 2002;40:458-63.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Laverman GD,Andersen S., Rossing P., Navis GJ, De Zeeuw D., Parving HH Dose-dependent reduction of proteinuria by losartan does not require reduction of blood pressure. (abstract) J Am Soc Nephrol 2002;13:265A.
  • Russo D., Pisani A., Balletta MM et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999;33:851-6.[Web of Science][Medline] [Order article via Infotrieve]
  • Russo D., Minutolo R., Pisani A. et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001;38:18-25.[Web of Science][Medline] [Order article via Infotrieve]
  • Mogensen CE, Neldam S., Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.[Abstract/Free Full Text]
  • Agarwal R. Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001;59:2282-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Laverman GD, Navis G., Henning RH, De Jong PE, De Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002;62:1020-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ruggenenti P., Brenner BM, Remuzzi G. Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion. Nephron 2001;88:254-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Zoja C., Corna D., Rottoli D. et al. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 2002;61:1635-45.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Remuzzi G., Zoja C., Gagliardini E., Corna D., Abbate M., Benigni A. Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 1999;10:1542-9.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 3, No. 4, 205-213 (2002)
DOI: 10.3317/jraas.2002.042
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 CJASNHome page
M. Azizi, J. Menard, A. Bissery, T.-T. Guyene, and A. Bura-Riviere
Hormonal and Hemodynamic Effects of Aliskiren and Valsartan and Their Combination in Sodium-Replete Normotensive Individuals
Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 947 - 955.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
L. Vogt, G. Navis, and D. de Zeeuw
Individual Titration for Maximal Blockade of the Renin-Angiotensin System in Proteinuric Patients: A Feasible Strategy?
J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S53 - S57.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
G. D. Laverman, G. Remuzzi, and P. Ruggenenti
ACE Inhibition versus Angiotensin Receptor Blockade: Which Is Better for Renal and Cardiovascular Protection?
J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S64 - 70.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Laverman, G. D
Right arrow Articles by Navis, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laverman, G. D
Right arrow Articles by Navis, G.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Kidney Diseases
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement